TREAT YOUR ELIGIBLE PATIENTS WITH FLEXIBILITY

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to 6 months (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable.

^†Stable patients switching to EYLEA 8 mg do not require loading doses and can maintain or extend previous treatment intervals after the first injection of EYLEA. Consult the SmPC for full posology.

Prescribing information for EYLEA® (aflibercept)

DMO, diabetic macular oedema. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q16, every 16 weeks. T&E, treat and extend. VEGF, vascular endothelial growth factor.